Matulis, Shannon M.
Gupta, Vikas A.
Neri, Paola
Bahlis, Nizar J.
Maciag, Paulo
Leverson, Joel D.
Heffner, Leonard T. Jr.
Lonial, Sagar
Nooka, Ajay K.
Kaufman, Jonathan L.
Boise, Lawrence H.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA192844, P30 CA138292)
Article History
Received: 6 August 2018
Revised: 19 October 2018
Accepted: 29 October 2018
First Online: 24 January 2019
Compliance with ethical standards
:
: NJB, funding and honorarium from Celgene and Janssen; PM and JDL, employment, Abbvie; LTH, research funding, Abbvie; SL, consultancy, Takeda, Celgene, Novartis, Abbvie, Amgen, Janssen, Bristol-Myers Squibb; AKN, advisory board or consultancy, Amgen, Adaptive Technologies, Janssen, Celgene, Spectrum Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Takeda; JLK, Consultancy, Abbvie, Janssen, Bristol-Myers Squibb, Takeda, Data Monitoring Committee, Karyopharm, Pharmacyclics; LHB, consultancy, Abbvie, honorarium, AstraZeneca. The other authors declare that they have no conflict of interest.